InvestSMART

PYC Therapeutics Limited (ASX:PYC)

ALERT: Price-sensitive ASX Announcement for PYC
Current share price for PYC : $1.535 0.155 (11.23%)+
Announcement
Release
24 Nov 2025 8:21AM
Price at Release
$1.380
Full Release
download
Summary
PYC Therapeutics Limited announced that it has received approval from the Safety Review Committee to escalate dosing in its ongoing PKD clinical trial. The trial involves a drug candidate known as PYC-003, which targets the underlying cause of Polycystic Kidney Disease (PKD). The approval follows a review of safety data from the first cohort and allows for dose escalation to the second cohort in Part B of the Single Ascending Dose (SAD) study. This trial is part of PYC's larger effort to develop RNA therapies for genetic diseases and aims to establish an optimal dosing regimen in preparation for a potential registrational Phase 2/3 trial.
Key Points
  • PYC is conducting clinical trials for a drug candidate PYC-003 targeting PKD.
  • Approval received to escalate dosing to the second cohort in the SAD study.
  • Safety Review Committee approved after reviewing 4-week safety data.
  • PYC-003 addresses underlying causes of PKD, part of RNA therapy development.
  • The trial will lead into an Open-Label Multiple Ascending Dose (MAD) study.
  • The aim is to find an optimal dosing regimen for a future Phase 2/3 trial.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.